Showing results (41-50 of 141) with videos related to
Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trialCyrille Hulin, Thierry Facon, Philippe Rodon, et al.Clinical Lymphoma, Myeloma & Leukemia|September 18, 2025
Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) CohortCyrille Hulin, Karim Belhadj Merzoug, Bruno Royer, et al.Blood|October 22, 2010
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?Hervé Avet-Loiseau, Florent Malard, Loic Campion, et al.Clinical Pharmacokinetics|September 29, 2012
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myelomaPhilippe Moreau, Ievgenii I Karamanesht, Natalia Domnikova, et al.British Journal of Haematology|May 29, 2024
Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03Aurore Perrot, Murielle Roussel, Valerie Lauwers-Cances, et al.Journal of Cancer Research and Clinical Oncology|August 28, 2020
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial resultsSaad Z Usmani, Maria-Victoria Mateos, Vania Hungria, et al.Health Science Reports|January 31, 2019
Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practiceCyrille Hulin, Javier de la Rubia, Meletios A Dimopoulos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)Hervé Avet-Loiseau, Xavier Leleu, Murielle Roussel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2017
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-AnalysisPhilip L McCarthy, Sarah A Holstein, Maria Teresa Petrucci, et al.British Journal of Haematology|November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II studyAjai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.Pageof 15